VYNE – vyne therapeutics inc. (US:NASDAQ)
Stock Stats
News
VYNE Therapeutics Inc. (NASDAQ: VYNE) is now covered by analysts at BTIG Research. They set a "buy" rating and a $8.00 price target on the stock.
VYNE Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
VYNE Therapeutics Inc. (NASDAQ: VYNE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.75 price target on the stock.
VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
We Think VYNE Therapeutics (NASDAQ:VYNE) Needs To Drive Business Growth Carefully [Yahoo! Finance]
Form SC 13G/A VYNE Therapeutics Inc. Filed by: Soleus Capital Master Fund, L.P.
Form ARS VYNE Therapeutics Inc. For: Dec 31
Form DEF 14A VYNE Therapeutics Inc. For: Dec 12
Form 10-Q VYNE Therapeutics Inc. For: Sep 30
Form 8-K VYNE Therapeutics Inc. For: Nov 07
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.